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Background & aims: The integrity of the intestinal barrier in the diseased is key to prevent further
complications and disease such as sepsis and death, whereas, the role of food bioactive molecules (i. e.
phenolic compounds (PCs) on the intestinal barrier, is still unknown. The current aim was to explore the
benefits of the oral PC administration on the intestinal barrier integrity in animals.
Methods: The effects of PCs on the intestinal barrier integrity in in vivo animal models of intestinal
inflammation were assessed up-to August 2020 from the PubMed, SCOPUS, and Cochrane Library da-
tabases under the PRISMA methodology. The risk of bias was assessed from ARRAY and SCYRCLE tools.
Results: From 1241 articles, 14 studies were included. In animals, oral resveratrol (n ¼ 6) improves the
intestinal barrier integrity and reduces intestinal damage. Additionally, grape seed extract (n ¼ 2), cur-
cumin (n ¼ 1), genistein (n ¼ 1), chlorogenic acid (n ¼ 1), grape pomace (n ¼ 1), olive leaf (n ¼ 1) or
cranberry extract (n ¼ 1) improve the intestinal barrier integrity downregulating various inflammatory
molecules (TNF-a, and other interleukins), and increasing the antioxidant enzymes in animals.
Furthermore, resveratrol, quercetin, epigallocatechin, and other PCs improve the epithelial barrier
integrity and pro-inflammatory molecule expression in the intestinal epithelia.
Conclusions: The oral PC administration in animals improves the intestinal barrier integrity and function
from three main mechanisms: 1) The reduction of pro-inflammatory molecules, 2) the improvement in
tight-junction protein expression, and 3) the improvement of the antioxidant intracellular activity
suggesting the potential use of PCs in the management of intestinal injury in humans, particularly for
resveratrol, the most studied PC.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The gastrointestinal tract is a key player in the pathogenesis of
the multiorgan dysfunction found in critically ill patients which is
secondary to the breakdown of the intestinal barrier, consequently
impairing its protective role. The loss of the intestinal barrier
integrity is common amongst critically ill patients causing higheric de Catalunya, Unitat de
Spain.
alan).
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írez, Ú. Catalan, A. Pedret et
ntegrity: A systematic reviewmortality rates when compared against individuals with a pre-
served intestinal barrier integrity [1].
On the other hand, during a life-threatening intestinal disease
such as necrotizing enterocolitis (NEC) in preterm infants [2], the
gastrointestinal tract epithelia is characterized for because of
increased permeability and inflammation secondary to an
augmented rate of apoptosis [3,4]. NEC is characterized by the
patchy necrosis of the small intestine with variable effects on the
colon that might progress to systemic sepsis, multisystem organ
failure, and finally death [2]. The increase in the intestinal perme-
ability, evidenced as an increased plasmatic lipopolysaccharideunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
al., Exploring the effects of phenolic compounds to reduce intestinal
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B.A. Sandoval-Ramírez, Ú. Catalan, A. Pedret et al. Clinical Nutrition xxx (xxxx) xxx(LPS) levels, is caused by the overexpression of different proteins
such as the toll-like receptor 4 (TLR4) [2].
Moreover, in humans, the intestinal gut integrity is disrupted
during critical illness [5,6]. The disruption is caused by an increased
intestinal permeability during critical illness from the down-
regulation of the B-cell lymphoma 2 (Bcl-2) protein expression
[7,8]. As has been demonstrated, the downregulation of Bcl-2 is
significantly associated with the necrosis and loss of function in the
intestines of septic transgenic mice, while the Bcl-2 overexpression
was associated with the inhibition of intestinal epithelial apoptosis
and the improvement of survival in septic mice [7,8]. Finally, in
animal models of critical illness the expression tight junction (TJ)
proteins such as claudin-2, claudin-5, and zonula occludens (ZO)-1
all decrease, further evidencing the loss of the intestinal barrier
integrity [9e11], thus demonstrating the importance of the TJ
proteins in the development of sepsis [12,13].
Consequently, new therapeutic approaches for improving the
intestinal integrity and barrier function are currently needed [14].
In that sense, the phenolic compounds (PCs) are a large group of
natural bioactive molecules or phytochemicals present in plants,
PCs including different sub-classes such as flavonoids, stilbenes,
phenolic acids, and lignans [15], with promising potential for the
treatment and prevention of diverse chronic diseases with an in-
flammatory component such as type 2 diabetes mellitus (T2DM),
cancer and cardiovascular disease (CVD) [16e18].
PCs are considered to be safe for human consumption due to
their low rates of adverse effects, even when consumed at high
doses [15,19e21], and their tissue bioavailability has been
confirmed after oral intake in diverse animals, suggesting that their
presence in diverse target tissues leads to their associated health
benefits [18].
From previous reviews, it has been demonstrated that in in vivo
animal studies, PCs and PC extracts can lower the severity of colitis
by modifying various intracellular signaling cascades in the intes-
tinal epithelium and showing anti-inflammatory effects [22].
Additionally, a clinical trial using pomegranate extract as a PC
source demonstrated to significantly reduce the plasmatic con-
centrations of the LPS-binding protein in humans, decreasing
endotoxemia in overweight-obese individuals who were suffering
from intestinal inflammation [23]. Furthermore, the supplemen-
tation with curcumin, a PC, has demonstrated to improve the in-
testinal disease activity in patients suffering from ulcerative colitis
partially from the reduction of oxidative stress in a randomized,
double-blinded, placebo-controlled pilot study [24]. In other
studies where healthy humans consumed wine with 1758 mg/L of
total polyphenols improved the expression of diverse pro-
inflammatory cytokines improving the intestinal barrier integrity
was demonstrated [25].
Due to the lack of a model able to precisely recreate the changes
occurring in human intestines during critical illness [26], diverse
animal models of induced intestinal damage and intestinal
inflammation were used to assess the potential benefits of PCs on
the intestinal barrier integrity during critical illness [3,27,28].
The present systematic review aims to explore the potential
effects of the oral PC administration on the intestinal barrier
integrity from in vivo animal models of induced intestinal damage.2. Materials and methods
2.1. Literature search
This systematic review is structured following the general
principles published in the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines [29]. The2
PRISMA flowchart (Fig. 1) and PRISMA checklist (Supplementary
Table 1) for the present systematic review are presented.
2.1.1. Information sources and search strategy
The scientific web libraries Scopus (https://www.scopus.com),
Cochrane Library (https://www.cochranelibrary.com/), and
PubMed (https://pubmed.ncbi.nlm.nih.gov/Error! Hyperlink refer-
ence not valid.) were explored. For the present systematic review
articles regarding the experimental use of PCs on human or in vivo
animal research was searched through the following terms:
“(phenolic compound OR polyphenol) AND (intestinal OR intestine
OR bowel OR jejunum OR duodenum OR colon) AND (barrier OR
disease OR inflammation OR inflammatory OR sepsis OR perme-
ability) AND (human OR in vivo) NOT (review)”.
2.1.2. Article's selection criteria
Our group identified the articles from the database search, du-
plicates were removed, and 3 additional articles were found by
hand-search. Published articles were screened based on their titles,
abstracts, and full texts according to the following inclusion
criteria:
1) in vivo animal studies regarding the effects of at least one PC on
the intestinal barrier integrity.
2) Studies where the effects of PCs were compared against both
positive and negative controls in in vivo animal models.
3) Studies published in the last 20 years, from January 1st 2000 up
to August 1st 2020.
The exclusion criteria were the following: 1) Non-English arti-
cles; 2) Low-quality after the risk of bias assessment for in vivo
animal studies; 2) incomplete data publication; 3) Review articles;
4) studies assessing the effects from the metabolization of phenolic
compounds by the intestinal microbiome, and 5) not fulfilling the
inclusion criteria. After full-text analysis, the following information
was extracted from the included articles: title, author information,
type of study performed, assessed outcome/s, intervention target
(animal used), administered dose, length of study, administration
route, doses administered, and main conclusions. Whenever
possible, the dose administered to animals was converted into its
human equivalent dose (HED) defined as the conversion of the
animal dose into its HED and expressed as the 24 h dose for an
average human being weighting 70.0 kg [30].
Under the PRISMA methodology, two independent authors
(B.A.S.-R. and U.C.) analyzed the titles, abstracts, and full-text arti-
cles for inclusion while a third reviewer (R.S.) resolved all differ-
ences if present.
2.1.3. Quality assessment
The reporting quality of the included animal study articles was
assessed and interpreted following the Animal Research Reporting
of In Vivo Experiments (ARRIVE) guidelines [31], while the risk of
bias for the included animal studies was assessed using the SCYR-
CLE's tool for assessing the risk of bias in animal studies [32].
3. Results
3.1. Literature search, study selection, and characteristics
From our initial database screening, 1241 articles published
from January 1st, 2000 up to August 1st, 2020 were retrieved from
all databases. All titles and abstracts were assessed; as a result, 1183
articles were excluded after the initial screening, 7 articles were
excluded as duplicates, 16 articles were excluded as in vitro studies,
5 publications were excluded for being reviews, 13 publicationś
Fig. 1. PRISMA flow diagram for the included studies.
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lization of PCs, and 1 experiment was excluded for not having a
control group leaving a total of 14 articles for final inclusion
[33e46].
The complete PRISMA statement flow diagram for the included
studies is presented in Fig.1. No studies performed on humanswere
found regarding the effects of the PC supplementation on the in-
testinal health and barrier integrity of critically ill humans.
The following information was retrieved from the included
studies:
Regarding the animal models used in the 14 included in vivo
animal studies: Wistar rats (n ¼ 4) [31,34,36,40], C57BL/10 SnSn
mice (n ¼ 1) [35], C57BL/6J mice (n ¼ 1) [37], both C57BL/6 and
IL-deficient mice (n ¼ 1) [38], both C57BL/6 and CD1 mice (n ¼ 1)
[41], C57BL/6 mice alone (n ¼ 1) [43], weaned pigs (n ¼ 2)
[33,44], SpragueeDawley rats (n ¼ 1) [32], IL-10 deficient mice
(n ¼ 1) [39], and BALB/C mice (n ¼ 1) [45]. The current animal
models used to assess intestinal inflammation are summarized in
Table 1.
Most of the included studies assessed different PCs individually,
with the exception of two studies where resveratrol and curcumin
were evaluated separately in the same experiment [35,46]. In
in vivo animal studies, resveratrol as an extract was the most3
commonly used source of PCs (n ¼ 6) [31,32,34,35,44,45]; after its
oral (n¼ 5) [31,34,35,44,45], or intravenous administration (n ¼ 1)
[32]. Other PC sources used in in vivo animal studies were: oral
grape seed extract (GSE) (n ¼ 2) [38,39], oral grape pomace extract
(n ¼ 1) [40], oral cranberry extract (n ¼ 1) [37], oral curcumin
(n ¼ 1) [35], oral hesperidin (n ¼ 1) [43], oral Olive (Olea europaea)
leaves extract (n ¼ 1) [41], genistein by intestinal injection (n ¼ 1)
[36], and oral chlorogenic acid (n ¼ 1) [33]. Complete information
on the included animal studies is reported in Table 2.3.1.1. Quality assessment
The reporting quality of the 14 included animal studies was
assessed through the ARRIVE guidelines. As a result it was
determined that the included animal articles adequately re-
ported their results. Moreover, the risk of bias of the 14 included
animal studies was assessed using the SCYRCLE's tool; as a
result, all the included articles were of moderate quality. None-
theless, after a thorough assessment of the included animal ar-
ticles, it was determined that despite their moderate score, there
is a low risk of bias in the included publications. The complete
results on the ARRIVE guidelines and SCYRCLE's tool for risk of
bias assessment are reported on Supplementary Tables 2 and 3,
respectively.
Table 1
Summary of the current models used to assess intestinal inflammation.
Model type Model sub-type Model used Description
Animal model
Knockout mice
IL-10 Involved in anti-inflammatory pathways
IL-23R Involved in T-cell differentiation
CD4þ CD25þ Involved in the T-cell glycoprotein adaptation
NOD2/CARD15 Peptidoglycan involved in apoptosis
TGF-b1 Involved in T-cell development and immune response regulation
RAG Involved in lymphocyte maturation
ATG16L1 Involved in pathogen regulation
APCMIN/þ Used for intestinal tumorogenesis
IL-2 Involved in the inflammatory process
TNF-a Involved in the activation of apoptosis
STAT3 Involved in intestinal mucosa regeneration
NFƙb Involved in inflammation and cell survival
MUC2 Involved in the production of mucin
IFN-ƴ Involved in the inflammatory process
MYD88 Involved in the signaling process for toll-like receptors and NFƙb
TLR Involved in the microbial surface identification
Rats Frequently employed along with the use of chemical agents to induce inflammation.
Furthermore, HLA-B27 models spontaneously develop intestinal inflammation
Nematodes and insects
Caenorhabditis elegans Caenorhabditis elegans has been used to examine hostemicrobiome interactions in apical
surface of intestinal epithelia cells.
Drosophila melanogaster Models have been used to explore the alterations in the innate immune response related to
chronic inflammation and cancer development
Fish
Zebrafish (Danio rerio) Zebrafish have been used to test adaptative and immune responses due to intestinal cell
similarities with mammalians such as the enterocytes, goblet cells and microvilli. Especially
useful for motility and peristaltic studies.
Pigs Pigs have been used because of their anatomical similarities with the human intestines,
particularly for the stomach and small intestine. However, several differences in the
expression of IFN-y, IL-12 and IL-10 production must be taken into consideration when
compared against humans.
Non-human primates
Macaques Non-human primate animal models are considered the gold standard for the study of the
mechanisms involved in chronic and acute inflammation due to the similarities in
physiology, immunology, anatomy, and the intestinal microbiome.
Surgical procedures
Xenograft The procedure involves the transplantation of fetal intestinal segments from one species
into another.
Cannulation Commonly applied to obtain gastrointestinal samples and to examine nutritional metrics.
Intestinal loops Are complex procedures useful to study hostepathogen interactions with an added
advantage of replicating the normal intestinal characteristics by creating intestinal
segments partitioned into “loops"
Chemical agents Dextran sulphate sodium Causes basal crypt and epithelial cell damage after long term administration with an
increase in the production of pro-inflammatory cytokines
Trinitrobenzene sulfonic acid Causes a Th1 mediated immune response with an increase in the production of pro-
inflammatory cytokines
Oxazolone Causes a Th2 mediated immune response with an increase of interleukins 4, 5, and 13.
Azoxymethane Commonly used in conjunction with dextran sulphate sodium to induce an increased
production of IL-21, IL-17a, and IL-6.
Biological agents
Bacteria Citrobacter rodentium Used to cause acute inflammation in the colon, producing ulcerative and proliferative
intestinal lesions
Helicobacter pylori Has been used for its ability to occupy the gastric and intestinal epithelia causing damage
after cytotoxin release in the presence of urease
Salmonella enterica Used to induce chronic models of intestinal inflammation in mice causing deep injury in the
intestinal layers
Mycobacterium avium Used to cause intestinal changes like the ones found in humans with Crohn's disease
Helminths Trichuris muris The most used nematode for intestinal inflammation in murine models, characterized for
the loss in barrier function of the colon
Protozoa Toxoplasma gondii Commonly used to cause a robust Th1 immune response in the small intestine resulting in
an increased expression of IL-12 and IFN-y
Note: IL, interleukin; IFN-y, interferon gamma; HLA, human leucocitary antigen; NFƙb, nuclear factor kappa beta; NOD2, nucleotide-binding oligomerization domain-
containing protein 2; CARD15, caspase recruitment domain-containing protein 15; TGF-b1, tumor growth factor beta 1; RAG, recombinant activation gene; ATG16L1,
autophagy related 16 like 1; TNF-a, tumor necrosis factor alpha; STAT3, signal transducer and activator of transcription 3; MUC2, mucin 2; MYD88, myeloid differentiation
primary response 88; TLR, toll like receptor.
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3.2.1. Resveratrol
The effects of resveratrol on the intestinal barrier were assessed
on seven different animal studies [33e35,41,45,53,55]. The animal4
models used were BALB/C mice (n ¼ 1) 32, Wistar rats (n ¼ 2)
[33,41], C57BL/6/10ScSn mice (n ¼ 1) [35], piglets (n ¼ 2) [45,55],
and SpragueeDawley rats (n ¼ 1) [34].
In a dextran sodium sulfate (DSS) colitis model induced for 14
days to 21 male BALB/C mice, the oral dietary supplementation
Table 2
General information of the included studies assessing the effects of polyphenols on the intestinal barrier integrity and intestinal health in diverse animal (in vivo) studies.
Title Author Year Outcome Intervention
target
N (m/f) Phenolic compound
used
Animal dose Human equivalent



















Ergün, O. et al. 2007 Nitric oxide synthase




27 (NR) Resveratrol 15 mg/kg/BID 85 mg/day 4 days Oral Oral PC treatment started
on day 0 and continued
for 4 days until animal
sacrifice. Necrotizing
enterocolitis was
provoked on day 0 using
a chemical agent and
from hypoxia with a 5%
oxygen room air until
sacrifice in day 4.
8 The resveratrol treated group showed no
changes in the macroscopic intestinal
appearance (intestinal edema,
pneumatosis intestinalis and ileal
necrosis). The Western blot analysis
revealed that resveratrol caused a
marked decrease in the elevation of the
NO synthase protein expression
(0.6 ± 5.1; p < 0.01), when compared
against the NEC group (3.7 ± 2.9). When
compared against the NEC group
(191.4 ± 4.1 mmol/L$g), resveratrol
significantly reduced the ileal nitrate/
nitrite levels (181 ± 3.6 mmol/L$g;
p < 0.01) in a significant manner.
The protective effect of
resveratrol on the
intestinal mucosal
barrier in rats with
severe acute
pancreatitis.




54 (m) Resveratrol 10 mg/kg 1.61 mg/day 12 h Intravenous One single PC dose was
administered on minute




1 The resveratrol treated animals showed
lower endotoxin levels at 3, 6, and 12 h
when compared against the pancreatitis
group (p < 0.05). At 12 h, resveratrol
significantly reduced the endotoxin
levels in z51% (p < 0.05), as well as the
pancreatic and intestinal mucosal
congestion, edema, inflammatory cell
infiltration, when compared against the
pancreatitis group (p < 0.05). The
intravenous administration of
resveratrol significantly lowered the
apoptotic cell index of the mucosal cells
(p < 0.05), decreased the expression of
the Bax protein (p < 0.05), and increased









2010 Intestinal inflammation C57BL/10ScSn
mice
NR Resveratrol 20 mg/day 1.62 mg/day 10 days Oral Oral PCs were
administered on day
0 until animal sacrifice in
day 10. The intestinal
inflammation (ileitis)
was induced in day 2
from a Toxoplasma
gondii inoculation.
10 After 19 days, the resveratrol group
showed higher survival rates (40%
survival; p < 0.005), when compared
against the control group (0% survival;
p < 0.005). Resveratrol significantly
decreased the animal weight loss in 9%
(11%; p < 0.005) when compared against
the control group (20%; p < 0.005). The
animals treated either with resveratrol
or curcumin presented only mild signs of
inflammation (edema and cell-free
exudate) in the visual exploration of the
ileal mucosa, while maintaining an
intact epithelium (p < 0.0001). Both
treatments reported a lower increase in
T lymphocytes (p < 0.05), a 20e30%
increase in the FOXP3þ cell numbers
(p < 0.05), and 25e50% fewer MPO-7þ
cells (p < 0.05), while significantly
reducing the total bacterial load in 1e2
orders of magnitude when compared
against the placebo control (p < 0.05).
Curcumin 100 mg/day 8.13 mg/day
Protective effect of soy
isoflavone genistein
on ischemia-
reperfusion in the rat
small intestine.




NR (m) Genistenin 500 mL NA NA Intestinal
injection
One single PC dose was
directly administered
into the intestinal lumen





1 Genistein significantly reduced the
damage and loss of villi to the intestinal
crypts (p < 0.05), mainly inhibiting the
intestinal xanthine oxidase activity, and
enhancing the reactive oxygen species
scavenging activity.















Table 2 (continued )
Title Author Year Outcome Intervention
target
N (m/f) Phenolic compound
used
Animal dose Human equivalent



















population in the gut
microbiota of mice
Anhê, F. et al. 2014 diet-induced intestinal
inflammation and
metabolic endotoxemia





200 mg/kg 1120 mg/day 8 weeks Oral Oral PC administration
started after a 2-week
acclimation period along
with a high fat and high
sucrose diet to induce
intestinal inflammation.
56 The oral administration of crandberry
extract completely prevented a twofold
increase in circulating levels LPS levels









Yang, G. et al. 2014 Ileal inflammation C57BL/6 mice
and IL-
deficient mice
NR (f) GSE 1% w/w
supplemented diet
NA 16 weeks Oral Oral PC administration
started on day 0 until
week 16. Intestinal
inflammation was
provoqued by the genetic
IL-10 deficiency.
112 The GSE decreased the intestinal crypt
depth (p < 0.05) and increased the ratio
of villus vs. crypt length in the terminal
ileum (p < 0.05). GSE significantly
decreased the proliferation and
enhanced the differentiation of the
intestinal epithelial cells (p < 0.05),
suppressing the NF-kb in activated B-
cells (p < 0.05). Finally, GSE significantly
reduced the intestinal cell autophagy by
decreasing the expression of beclin-1
(p < 0.05).











NR (f) GSE 140 mg/kg/day 798 mg/day 12 weeks Oral Oral PC administration
started on day 0 until the
end of week 12 when
animals were sacrificed.
Intestinal inflammation
was provoqued by IL-10
deficiency
84 After 12 weeks of oral GSE
supplementation with 140 or 160 mg/
kg/day in mice, the in vivo intestinal
permeability significantly decreased
with additional reductions in the fecal
total antioxidant capacity, and serum
TNF-a levels (p < 0.01). In addition, the
GSE significantly reduced the number of
proliferating nuclear antigen-positive
cells per crypt (p < 0.01), and
downregulated the MAP kinase's growth
signaling in the colon (p < 0.01).
160 mg/kg/day 910 mg/day
Dietary Supplementation





Induced Colitis in Rats
Boussena, A.
et al.
2016 dextran sulfate sodium
(DSS)-induced colitis in
rats
Wistar rats 40 Grape pomace
extract (GPE)
0.1%, 0.5% and 1% NA 21 Oral Oral PCs were
administered from day
0 until day 21, colitis was
induced on day 14 from
DSS oral administration.
21 The GPE 0.1% diet significantly delayed
the onset of colitis symptoms, prevented
the decrease in food intake, weight loss,
the colon shortening, and the
polimorphonuclear infiltration of the
intestinal wall when compared against
the positive control group. 0.5% and 1%















60 (m) Resveratrol 10 mg/kg 112 mg/day 7 days Oral One single PC dose was
administered orally after
bile duct ligation to cause
intestinal inflammation
1 When compared against the control
group (3.19 ± 0.90), both resveratrol
treatments significantly decreased the
intestinal permeability as evidenced in
the decrease of the lactulose/mannitol
ratio in 70.5% by the 10 mg/kg dose
(0.94 ± 0.43; p < 0.05), and in 86.8% by
the 20 mg/kg dose (0.42 ± 0.25;
p < 0.05). Resveratrol upregulated the
hemeoxygenase-1 protein expression
ameliorating the TJ protein disruption
(p < 0.05).






Vezza, T. et al. 2017 dextran sulfate sodium-
induced intestinal
inflammation
C57BL/6J NR (m) Olive (Olea
europaea) leaves
extract
0.5, 1, and 10 mg/kg 2.8, 5.6, and 56 mg/
day
11 Oral PC doses started at day
0 and were administered
until animal sacrifice on
day 11. Intestinal
inflammation was
induced on day 0 until
sacrifice on day 11 using
DSS.
11 The olive leaf extract at 1 and 10 mg/kg
doses significantly improved the
evolution of the colitis severity,
enhanced the intestinal functionality
from the improvement of intestinal
permeability assessed by FITC-dextran
permeability. Additionally, the olive leaf
extract improved epithelial
regeneration, reduced the inflammatory



















CD1 mice NR (m) Olive (Olea
europaea) leaves
extract
1, 10, and 25 mg/kg 5.6, 56, and 140 mg/
day
6 Oral PC doses started on day
0 and were administered





acid on day 2 and
continued until sacrifice
on day 6.
6 The olive leaf extract 1 mg/kg dose
significantly improved inflammation in
the colon of treated mice, reduced the
expression of IL-1b, TNF-a, IL-6, IL-17,
and MIP-2. Additionally, the olive leaf
extract significantly upregulated the
ICAM-1, inducible nitric oxide synthase
(iNOS) and cyclooxygenase-2 (COX-2) in









2018 Intestinal barrier defects
and inflammation
BALB/C mice 21 (m) Resveratrol 0.1% w/w
supplemented diet
NA 14 days Oral Oral PC administration
started at day 0 and
continued until day 14
when animals were
sacrificed
14 When compared against the control,
resveratrol significantly prevented the
body weight loss in 28% (100 ± 1%;
p < 0.05), the shortening of the colon
length in 0.8 cm (4.6 ± 0.1 cm; p < 0.05).
Additionally, resveratrol reduced the
plasmatic levels of IL-1b in 89.9%
(5.9 ± 1.8 AU; p < 0.05) and of IL-6 in 96%
(10 ± 3 AU; p < 0.05). Resveratrol
reduced the expression of the CXCL-2
(14 ± 7 AU; p < 0.05), increased the
expression of occludin (0.76 ± 0.06 AU;
p < 0.05), and reduced the neutrophil









Chen, J. et al. 2018 Intestinal barrier
function
Weaned pig 24 (NR) Chlorogenic acid 1000 mg/kg/day 38.85 g/day 2 weeks Oral Oral PC administration
started at 24 days of age
when pigs were weaned
and continued for 2
weeks until animal
sacrifice.
14 Chlorogenic acid significantly decreased
the serum D-lactic acid content and
diaminooxidase activity (p < 0.05).
Chlorogenic acid showed a tendency for
lower endotoxin levels (p < 0.10),
however, no significant differences in
the levels of cortisol and corticotrophin-
releasing hormone were observed
between the two groups. Chlorogenic
acid reduced the histamine contents in
the jejunum and ileum (p < 0.05), while
reducing the tryptase levels only in the
jejunum (p < 0.05). Significant decreases
in the counts of tryptase-positive mast
cells in the duodenum and jejunum of
pigs were noted after the chlorogenic
acid supplementation (p < 0.05).
Moreover, chlorogenic acid also
downregulated the expression of IL-1b
and TNF-a in the small intestine of pigs
(p < 0.05), of the IL-6 and TNF-a levels in
the ileum (p < 0.05), and up-regulated
the jejunal and ileal expression of
claudin-1. Finally chlorogenic acid
downregulated the expression of diverse
inflammatory proteins such as IL-23p19









Cao, S. et al. 2019 Intestinal injury induced
by diquat (herbicide)
Piglets 24 Resveratrol 100 mg/kg/day 4.97 g/day 14 days Oral Oral PC administration
started on day 0 until day






13 Resveratrol significantly increased the
total intestinal antioxidant capacity in
treated piglets. Additionally, oral
resveratrol reversed the increase in the
mucosal concentration of hydrogen
peroxide and malondialdehyde in the
jejunum. The oral resveratrol
administration also improved the
intestinal barrier function evidenced as
an improvement in the TEER reduction
provoqued by the herbicide. Moreover,
resveratrol prevented reduction of
occludin, claudin-1 and ZO-1 levels in
the jejunal mucosa.
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with resveratrol 0.1% (w/w) resulted in a 28% reduction of the an-
imal's weight loss (100 ± 1%; p < 0.05), and prevented the colon
shortening by 0.8 cm (4.6 ± 0.1 cm; p < 0.05) when compared
against the untreated control group [53]. Additionally, oral resver-
atrol reduced the plasmatic interleukin (IL)-1b concentrations in
89.9% (5.9 ± 1.8 arbitrary units (AU); p < 0.05), and the plasmatic IL-
6 concentrations in 96% (10 ± 3 AU; p < 0.05) [53].
Additionally, a single oral resveratrol dose of either 10 or 20 mg/
kg (HED: 112 or 125 mg/day) of resveratrol on the intestinal barrier
integrity was appraised 1 week after its administration to 60 male
Wistar rats with severe intestinal damage induced by the bile duct
ligation (BDL) [41]. As a result, the treatment with resveratrol
10 mg/kg significantly decreased the intestinal permeability in 6%
(0.94 ± 0.43; p < 0.05) while the 20 mg/kg dose decreased the
intestinal permeability of Wistar rats in 58% (0.42 ± 0.25; p < 0.05)
when compared against the BDL control group (3.19 ± 0.90) [41].
Finally, a single oral resveratrol dose of 20 mg/kg dose, significantly
upregulated the heme oxygenase (HO)-1 protein, improving the
intestinal antioxidant capacity (p < 0.05) when compared against
the BDL controls [41].
The effects of an oral 15 mg/kg resveratrol dose (HED: 85 mg/
day) twice for 4 days were assessed in a necrotizing enterocolitis
(NEC) model developed on 27 newbornWistar rats [33]. As a result,
the NEC Wistar rats treated with resveratrol showed no changes in
their macroscopic intestinal appearance, whereas the rats on the
non-treated NEC group presented different degrees of intestinal
edema, pneumatosis intestinalis and ileal necrosis [33]. Addition-
ally, the Western blot analysis revealed that resveratrol in NEC
Wistar rats caused a marked decrease in the elevation of the nitric
oxide (NO) synthase protein expression (0.6 ± 5.1; p < 0.01) when
compared against the NEC control group (3.7 ± 2.9) [33]. Finally,
when compared against the NEC Wistar rat group [191.4 ± 4.1
mmol/(L$g)], 15 mg oral resveratrol dose twice daily for 4 days
significantly reduced the ileal nitrate/nitrite levels [181 ± 3.6 mmol/
(L$g); p < 0.01] [33].
The intestinal effects of the oral supplementation with either
resveratrol 20 mg/day (HED: 1.62 mg/day) or curcumin 100 mg/day
(HED: 8.13mg/day), and simvastatin for 10 dayswere assessed from
the intestines of C57BL/10ScSn mice, an animal model commonly
used to study inflammation [35]. As a result, on the 8th day after the
induction of an acute ileitis with Toxoplasma gondii; the resveratrol,
curcumin, and simvastatin treated C57BL/10ScSn mice showed
lesser hyper-acute inflammation in the small intestine [35]. At 10
days, the end of the intervention, the resveratrol treated group
showed higher survival rates (40% survival; p < 0.005), when
compared against the control group (0% survival; p < 0.005) [35].
Additionally, in C57BL/10ScSn mice, resveratrol significantly
decreased the weight loss by 9% (11%; p < 0.005) when compared
against the control group (20%; p < 0.005) [35]. The C57BL/10ScSn
mice treated either with resveratrol or curcumin presented only
mild signs of inflammation (edema and cell-free exudate) in the
visual exploration of the ileal mucosa while maintaining an intact
epithelium (p < 0.0001) [35]. Both treatments, curcumin or
resveratrol, reported a lower increase in T lymphocytes (p < 0.05), a
20e30% increase in the numbers of a T regulatory lymphocyte cell
sub-type important for the immune system's tolerance and ho-
meostasis called FOXP3þ cells (p < 0.05), and 25e50% fewer
myeloperoxidase (MPO)-7þ cells (p < 0.05), while significantly
reducing the total serum bacterial load in 1e2 orders of magnitude
when compared against the placebo control C57BL/10ScSn mice
(p ¼ 0.05) [35].
The effects of a single 10 mg/kg (HED: 1.61 mg/kg) intravenous
resveratrol dose on the intestinal barrier integrity were assessed in
54 male SpragueeDawley rats after the induction of severe acute
pancreatitis induced by the clipping of the bile and biliopancreatic
B.A. Sandoval-Ramírez, Ú. Catalan, A. Pedret et al. Clinical Nutrition xxx (xxxx) xxxducts [34]. As a result, the intravenous treatment of severe
pancreatitis using resveratrol on SpragueeDawley rats showed
lower endotoxin levels at 3, 6, and 12 h when compared against the
pancreatitis control group (p < 0.05) [34]. At 12 h of intravenous
administration, resveratrol significantly reduced the endotoxin
levels in z51% (p < 0.05) [34], as well as the pancreatic and in-
testinal mucosal congestion, edema, and the inflammatory cell
infiltration, when compared against the pancreatitis control group
(p < 0.05) [34]. The intravenous administration of resveratrol
significantly lowered the apoptotic cell index of the mucosal cells
(p < 0.05) [34], decreased the expression of the Bax protein
(p < 0.05) [34], and increased the expression of the Bcl-2 protein
compared with SpragueeDawley rats with severe pancreatitis as a
control [34].
The effects of a resveratrol 100 mg/kg/day (HED: 4.97 g/day) on
the intestinal inflammation induced by diquat, a herbicide, were
assessed on 24 piglets [45]. For the experiment, the oral resveratrol
administration started on day 0 until day 13 along with diquat to
induce intestinal inflammation, the effects were compared against
a diquat-free control group [45]. As a result, resveratrol signifi-
cantly increased the intestinal antioxidant capacity, in addition,
resveratrol reversed the increased concentrations of hydrogen
peroxide and malondialdehyde caused by diquat in the jejunum
[45]. Moreover, resveratrol improved the intestinal barrier function,
evidenced as an improvement in the TEER reduction secondary to
diquat administration [45]. Finally, resveratrol prevented the
reduction of various TJ proteins in the jejunal mucosa (occludin,
claudin-1, ZO-1) [45].
3.2.2. Grape seed extract (GSE) and grape pomace extract (GPE)
The effects of GSE on the intestinal health were assessed from 2
animal interventions [38,39]. In mice, after 12 weeks of oral GSE
supplementation with 140 or 160 mg/kg/day (HED: 798 or 910 mg/
day respectively), the in vivo intestinal permeability significantly
decreased while additionally increasing the fecal total antioxidant
capacity, and serum TNF-a levels (p < 0.01) compared with the
untreated group as a control [39]. Also, the GSE significantly
reduced the number of proliferating nuclear antigen-positive cells
per crypt (p < 0.01) and downregulated the mitogen-activated
protein (MAP) kinase's growth signaling evidenced the reduced
phosphorylation of the extracellular signal-regulated kinases 1 and
2 (ERK1/2) in the colon (p < 0.01) compared with the control mice
[39].
In another mice experiment, interleukin (IL)-10-deficient and
C57BL/6 wild type female mice as a multi-hit model where a col-
itogenic trigger initiates the inflammatory process [56], were used
to test the effects of the oral water supplementation with GSE at
0.1% w/w on the ileal inflammation [38]. As a result in IL-10-
deficient mice, GSE significantly decreased the intestinal crypt
depth (p < 0.05) and increased the villus vs. crypt length ratio in the
terminal ileum of animals (p < 0.05) when compared against wild
type mice used as controls [38]. Furthermore, in separate IL10-
deficient mice, the oral GSE administration significantly
decreased the proliferation and enhanced the differentiation of the
intestinal epithelial cells (p < 0.05), suppressing the nuclear factor
kappa-light-chain-enhancer (NF-kb) in activated B-cells (p < 0.05)
compared against the GSE free control group [38]. Finally, oral GSE
significantly reduced the intestinal cell autophagy by decreasing
the expression of beclin-1 (p < 0.05) when compared against
C57BL/6 wild type mice as a control [38]. Thus, oral GSE exerts
protective effects on the ileal epithelial structure in IL-10-deficient
mice, possibly through the suppression of the intestinal inflam-
matory response.
The effects from the oral administration of various GPE doses
(0.1%, 0.5%, and 1%) on the intestinal inflammation secondary to the9
DSS oral administration were assessed on 40 Wistar rats, for the
experiment GPE was administered from day 0 until day 21, on day
14 colitis was induced from the DSS oral administration [40]. As a
result, GPE 0.1% significantly delayed the onset of colitis symptoms,
prevented the decrease in food intake, animal weight loss, colon
shortening, and the polymorphonuclear infiltration of the intestinal
wall when compared against the positive control group [40]. The
other GPE doses (0.5% and 1%) did not show the same effects [40].
3.2.3. Other phenolic compounds
The effects of oral chlorogenic acid on the intestinal barrier
integrity were assessed in an experiment where a dose of
1000 mg/kg/day (HED: 38.85 g/day) of chlorogenic acid, a natural
polyphenol present in human diet and plants, was orally admin-
istered to 24 weaned pigs for 14 days, as weaning is considered a
cause of intestinal inflammation [44]. As a result, oral chlorogenic
acid decreased the serum D-lactic acid content and diamine oxi-
dase activity (p < 0.05), while showing a tendency for lower
endotoxin levels (p < 0.10) when compared with the control
group without oral chlorogenic acid [44]. No significant differ-
ences in the levels of cortisol and corticotrophin-releasing hor-
mone were observed between the two weaned pig groups [44].
Moreover, oral chlorogenic acid reduced the histamine contents in
the jejunum and ileum of weaned pigs (p < 0.05), while reducing
the tryptase levels only in the jejunum of the treated animals
(p < 0.05) when compared against the control group [44]. After
chlorogenic the acid intake, significant decreases in the counts of
tryptase-positive mast cells in the duodenum and jejunum of the
weaned pigs were noted when compared against the control
group (p < 0.05) [44]. Moreover, the chlorogenic acid consump-
tion also downregulated the expression of IL-1b and TNF-a in the
small intestine of the treated weaned pigs (p < 0.05), the IL-6 and
TNF-a levels in the ileum of treated pigs (p < 0.05) [44], and up-
regulated the jejunal and ileal expression of claudin-1 in the
supplemented animals [44]. However, the expression of inflam-
mation repressors (suppressor of cytokine signaling 1 and toll-
interacting protein) was up-regulated by the chlorogenic acid
administration whereas chlorogenic acid downregulated the
expression of diverse inflammatory proteins such as IL-23p19
(p < 0.001), and TNF-a (p < 0.01) compared against the weaned
pig control [44]. The results suggest that oral chlorogenic acid
ameliorates the intestinal barrier disruption in weaned pigs
mediated by the suppression of the toll-like receptor (TLR)4/NF-
kb and the activation of the nuclear factor erythroid 2-related
factor 2 (Nrf2)/HO-1 signaling pathways [44].
Urolithin A, a major gut microbial PC metabolite derived from
the transformation of the ellagitannins in berries and pomegranate
fruits showing anti-inflammatory, anti-oxidative, and anti-aging
activities in Caenorhabditis elegans [57] was also studied. The ef-
fects of urolithin A on the intestinal barrier function were assessed
in one experiment where five urolithin A doses of 20 mg/kg (HEA:
1.62mg/kg) were administered at 0 h, 6 h, 12 h,18 h, and 24 h while
LPS was administered intraperitoneally to induce inflammation at
hour 24 in C57BL/6 wild type, Nrf2/, and AhR/mice [54]. As a
result, urolithin A significantly modified the expression of 437
different genes (p < 0.05), mainly in the eukaryotic initiation factor
2 (eIF2), mammalian target of rapamycin (mTOR), and mitochon-
drial dysfunction pathways in C57BL/6 mice [54]. Moreover, uroli-
thin A significantly upregulated the expression of claudin-4
(p < 0.05), Cyp1A1 (p < 0.05), and HO-1 (p < 0.05) in all mice
when compared against baseline values. Finally, urolithin A
significantly improved the intestinal TJ health through the activa-
tion of the aryl hydrocarbon receptor (AhR) - nuclear factor
erythroid 2erelated factor 2 (Nrf2)-dependent pathways [54], and
attenuated colitis in wild type, Nrf2/, and AhR/ mice by
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inflammatory activities [54].
The effects of genistein, a phytoestrogen part of the isoflavonone
family, on the intestinal barrier integrity were assessed in an in-
testinal injury model on Wistar rats [36]. For this experiment, the
Wistar rats were divided into two groups; one of them was pre-
treated with a single intestinal injection of 500 mL of genistein,
while the second group received a placebo treatment with saline
solution [36]. After the single intestinal injection, an ischemia-
reperfusion injury was induced in both groups, then the animals
were euthanized and the oxidative status and epithelial integrity
were assessed [36]. As a result, the single intestinal genistein in-
jection significantly reduced the damage and loss of villi to the
intestinal crypts (p < 0.05) [36], mainly inhibiting the intestinal
xanthine oxidase activity, and enhancing the reactive oxygen spe-
cies scavenging activity [36].
The effects of an olive leaf extract (OLE) were assessed on two
models of intestinal inflammation [42]. For the first model an OLE
dose of 0.5, 1 or 10 mg/kg (HED: 0.04, 0.08 or 0.8 mg/kg) was
administered on a colitis model induced by DSS in C57BL/6J mice
starting at day 0 until animal sacrifice in day 11 [42]. As a result, OLE
at 1 and 10 mg/kg doses significantly improved the colitis severity,
and enhanced the intestinal functionality from an improvement in
the intestinal permeability [42]. Additionally, OLE improved
epithelial regeneration, reduced inflammatory cell infiltration, and
edema in the intestinal mucosa of the treated animals [42]. In the
second model, OLE doses of 1, 10 or 25 mg/kg (HED: 0.08, 0.8, or
2 mg/kg) starting at day 0 until animal sacrifice were used. OLE was
administered daily to CD1 mice with induced colitis from the oral
administration of dinitrobenzene sulfonic acid at day 2 and was
continued until animal sacrifice on day 6 [42]. As a result, 1 mg/kg
dose significantly improved the intestinal inflammation of treated
mice, reduced the intestinal expression of IL-1b, TNF-a, IL-6, IL-17,
and the macrophage inflammatory protein (MIP)-2. Additionally,
the OLE significantly upregulated intracellular adhesion molecule
(ICAM)-1 expression, the inducible nitric oxide synthaseFig. 2. The main effects of phenolic compounds (PCs) on the intestinal health and barrier fu
the intestinal permeability, increasing the expression of different tight junction proteins
resulting in the reduction of intestinal tissue damage, healthier cytological characteristics, l
extracellular signal-regulated kinase; JNK, Janus kinase; Bax; Bcl-2, B-cell lymphoma 2; TN
10(iNOS), and cyclooxygenase (COX) 2 in the intestines of the treated
animals [42].
The effects of the oral administration of a daily 10, 20, or
40 mg/kg hesperidin doses (HED: 0.8, 1.6, or 3.2 mg/kg) on a DSS-
induced intestinal inflammation were assessed on 30 C57BL/6
mice [46]. For the treatment, the hesperidin doses were admin-
istered from day 0 until day 13, while the intestinal inflammation
was induced from day 0 until day 7 from the oral DSS adminis-
tration [46]. As a result, hesperidin was able to significantly
reduce the disease activity score and the pathological changes
provoked by DSS in the intestines of untreated animals such as
edema, hyperemia, inflammatory cell infiltration, and necrosis
[46]. In addition, hesperidin significantly decreased the TNF-a, IL-
6, and increased IL-10 and IFN-a concentrations in the intestines
of treated animals [46].
Finally, the effects of the oral administration of a 200 mg/kg
(HED: 16 mg/kg/day) dose of a cranberry extract on the diet-
induced intestinal inflammation and metabolic endotoxemia pro-
voked by a high-fat high sucrose diet in 36 C57BL/6J mice were
assessed [37]. For the experiment, the cranberry extract was
administered along with a high fat and high sucrose diet for 8
weeks [37]. As a result, the cranberry completely prevented the
two-fold increase in the circulating LPS levels after 8 weeks of the
high fat/high sucrose diet in the treated animals when compared
against the control group [37].
Notably, no side effects were observed for any of the PCs
administered in all the included articles even when the PCs were
given at doses only achievable from the PC extract administration
[33e40,42e46,54,55].
The effects of the oral administration of resveratrol and other
PCs on the intestinal barrier integrity are summarized in Fig. 2.
4. Discussion
The nutrition of patients is a vital necessity that should be
treated as such [58]. In that sense, early enteral nutrition (EN) isnction. The ingestion of various different PCs has demonstrated to significantly reduce
and modulating the expression of various pro-inflammatory or antioxidant proteins
esser neutrophil infiltration, and an improved antioxidant capacity. Abbreviations: ERK,
F-a, tumor necrosis factor alpha; IL; CXCL-2, Macrophage Inflammatory Protein 2.
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reduce the mortality rates in intensive care units, helping to
maintain the integrity of the intestinal barrier, leading to fewer
gastrointestinal hemorrhages, infectious complications, the sub-
sequent organ failure, and finally death in critically ill patients
[59,60]; suggesting that composition of EN formulae is one area of
medical interest.
As evidenced by the present systematic review, various PCs
seem to have promising beneficial effects on the intestinal
inflammation. For instance, it has been demonstrated that in
animal models, the oral administration of various PCs at
different doses significantly decreases various macroscopic
signs of intestinal inflammation [33e36,38,39,53]. For instance,
oral resveratrol significantly improves the intestinal edema,
pneumatosis intestinalis, and ileal necrosis in newborn rats
with necrotizing enterocolitis [33], the mucosal congestion,
edema, and inflammatory cell infiltration in adult rats with
intestinal inflammation secondary to acute pancreatitis [34],
and also in C57BL/10ScSn mice with acute intestinal inflam-
mation [35].
Additionally, resveratrol, genistein, and the oral GSE demon-
strated to improve various characteristics of the intestinal epithe-
lium such as the villus/crypt ratio, and crypt depth, in IL-10
deficient mice, Wistar rats and BALB/C mice [36,38,39,53] sug-
gesting the improvement of the intestinal functionality and struc-
ture in diverse animal models. Thus, PCs might promote various
beneficial effects to treat the decrease of the intestinal crypt pro-
liferation and crypt/callus axis that occurs in critical patients sec-
ondary to systemic inflammation that leads to the reduction of the
intestinal villus length which, in turn, causes nutrient malabsorp-
tion [2,12,13].
From all comments, the improvements in the intestinal function
and structure after the oral PC administration seem to be caused by
three main mechanisms in accordance with the information ob-
tained from this review:
First, PCs improve the expression of various pro-inflammatory
molecules as has been evidenced for resveratrol which improves
the expression of pro-inflammatory proteins such as TNF-a, IL-1b,
IL-6, and CXCL-2 in a dose-dependent manner [53]. Similar im-
provements on the intestinal cell expression of pro-inflammatory
molecules have been observed for other PCs, for instance, GSE
demonstrated to therapeutically improve the intestinal concen-
trations of TNF-a after 12 weeks of supplementation to IL-10 defi-
cient mice [39]. Additionally, the oral administration of an olive leaf
extract improved the expression of IL-1b, TNF-a, IL-6, and IL-17 in
mice when administered in conjunction with the induction of co-
litis for 6 days [42]. Finally chlorogenic acid significantly improved
the expression of endotoxin, histamine, tryptase, IL-1b, TNF-a, and
IL-6 concentrations in the duodenum, jejunum, or ileum in various
segments of the intestines of weaned pigs [44].
The reduced secretion of pro-inflammatory molecules in the
intestinal epithelium of animals treated with PCs is evidenced as a
smaller neutrophil infiltration rate in Wistar rats with intestinal
inflammation secondary to bile duct ligation [41], lower T lym-
phocytes and MPO-7þ cells counts, as well as additional increases
in the FOXP3þ cell numbers in the intestinal epithelium of C57BL/
10ScSn mice treated with curcumin or resveratrol [35].
It must be noted that further benefits from oral PCs on the in-
testinal inflammatory profile might come from the improvement in
the activity of proteins related to the inflammatory process as
demonstrated after the olive leaf extract administration which
significantly upregulated the expression of ICAM-1, iNOS, and COX-
2 in the intestines of C57BL/6J and CD1 mice [42]. Such anti-
inflammatory properties of PCs might constitute one of the most
important mechanism of action for the improvement of intestinal11health observed in IL-10 deficient mice [39], weaned pigs [44],
Wistar rats [41], and C57BL/6J and CD1 mice [42].
Second, PCs improve the expression or prevent the reduction of
different TJ proteins in the intestinal epithelium as demonstrated
for resveratrol which significantly improved the protein expression
of occludin in BALB/c mice [53], ameliorated the TJ protein
disruption by upregulating the expression of antioxidant enzymes
such as HO-1 in rats with intestinal inflammation secondary to bile
duct ligation [41], and prevented the reduction of occludin, claudin-
1 and zonula occludens (ZO)-1 levels in the jejunal mucosa of
piglets with herbicide-induced intestinal inflammation [45].
Additionally, the prevention of the reduction of occludin, claudin-1
and ZO-1 levels in the jejunal mucosa is the mechanism that
counteracts the alterations in the expression of various TJ proteins
causes by inflammation such as the increase in the expression of
claudin-2, and the decrease of claudin-5 and the ZO-1 proteins,
possibly preventing the loss in the intestinal barrier function that
characterizes critically ill patients [9e11] and in consequence
possibly improving the intestinal permeability.
Third, PCs decrease the concentration of reactive oxygen species
by increasing the activity of antioxidant enzymes such as HO-1 and
xanthine oxidase as demonstrated in Wistar rats with intestinal
inflammation and treated with resveratrol [41] or genistein [36]
respectively, suggesting that the antioxidant benefits observed
from the oral PC administration do not come only from their
chemical structure but also from their metabolic regulatory
activities.
Noticeably, the intestinal beneficial effects of PCs can also be
attained from the intravenous administration of resveratrol which
significantly lowered the endotoxin levels in plasma, as well as the
intestinal edema, the inflammatory cell infiltration, and the
apoptotic index of intestinal cells by improving the expression of
pro-apoptotic proteins such as Bax and Bcl-2 in intestinal damage
secondary to severe pancreatitis in SpragueeDawley rats [34]. This
might be of human benefit for the treatment of the increase in the
intestinal apoptosis in critically ill patients where the intestinal
disfunction has demonstrated to be regulated by a decreased
expression of the Bcl-2 protein, causing intestinal necrosis and loss
of function [7,8].
In accordance with the animal results, the in vitro evidence for
resveratrol demonstrates that their oral administration signifi-
cantly reduces the trans epithelial electrical resistance (TEER)
provoked by different noxious agents in induced pluripotent cells
(IPC)-J2 and caco-2 cells [51], counteracting their deleterious effects
on diverse signaling proteins such as ERK, JNK, and p38 [51]. Similar
cell effects were observed for other PCs [48,52].
Moreover, several in vitro studies provide other evidence sug-
gesting that PCs improve the intestinal barrier integrity. For
instance, a 20 mg/mL concentration of a proanthocyanin-rich purple
potato extract significantly increased the expression of occludin,
claudin-1, and the ZO-1 TJ proteins in caco-2 colon cancer cells [47].
Moreover, the same proanthocyanin-rich purple potato extract
significantly increased the production of different intestinal tran-
scription factors such as Elf3, and Hes1, demonstrating that
different PCs can enhance the epithelial barrier integrity by
increasing epithelial cell differentiation in caco-2 cells [47]. Finally,
the extracts from three different passion fruits [48], routin extract
[49], quercetin extract [49], epigallocatechin extract [49], and
resveratrol extract [50,51], all demonstrated to be capable of
increasing the TEER values, reflecting a better intestinal barrier
integrity in in vitro models of intestinal damage [48e51].
The reduction of apoptosis, the increase of the villus length, and
an increased expression of different TJ proteins coming from the
early oral administration of PCs might counteract the increase in
gut permeability that starts within the 1st hour of critical illness
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of the intestinal permeability might lead to lesser bacterial trans-
location, which in turn would reduce the subsequent systemic
infection and distant organ damage [62], thus, the animal results
suggest that the PC administration, through an oral or intravenous
pathway might improve the intestinal integrity and barrier func-
tion of critically ill patients and possibly other patients suffering
from intestinal inflammation [14].
From the above mentioned comments, the oral PC administra-
tion seems to exert beneficial effects directly from their interaction
with diverse intracellular proteins in the intestinal epithelium
[33e46]. However, it must be noted that the intestinal metabo-
lization of PCs might also be of paramount importance for the in-
testinal barrier integrity since many of the PC's beneficial effects on
the intestines might be caused by the first- or second-pass
metabolization by the intestinal microbiota resulting in a more
varied PC profile in the intestinal lumen of animals [63]. For
instance, urolithin A, a PC resulting from the ellagitannin trans-
formation by gut microbiota [64], significantly improved the in-
testinal barrier integrity, upregulating the expression of the TJ
protein, claudin-4, and also the antioxidant enzyme HO-1, from the
activation of the AhR-Nrf2 dependent pathway in mice with in-
testinal inflammation secondary to LPS injection [54].
Additionally, similar results on the improvement of TJ proteins
were reported for curcumin and resveratrol when tested in com-
bination with an antibiotic to assess the role of the intestinal
microbiota in the alleviation of intestinal inflammation in 180 hy-
brids weaned piglets [55]. As a result of the intervention, curcumin
and resveratrol at 300 mg/kg doses were able to significantly
regulate the gut microbiota and reduced the intestinal inflamma-
tion from the decrease in the expression of the TLR4 signaling
pathway in the jejunum and ileum of weaned piglets [55].
In same study, curcumin and resveratrol at all doses significantly
reduced the IL-1b, TNF-a, while improving the IL-10, IgG, and IgA
(p < 0.05) concentrations in the intestines of weaned pigs, thus,
demonstrating not only that PCs might play a beneficial role for
intestinal health but also the important role of the intestinal
microbiota on the intestinal barrier health and function [55].
Therefore, as a result of the present systematic review of animal
studies, it has become ostensible that the oral PC administration has
the potential for improving the intestinal barrier integrity during se-
vere inflammation, from an improvement in the inflammatory profile
in intestinal epithelial cells, increasing the TJ protein expression thus
reducing the intestinal permeability, and improving antioxidation in
the intestinal epithelia. In consequence, the translation of PC animal
results into humanhealth problems suggests a possible improvement
in the intestinal barrier function, possibly reducing further compli-
cations such as sepsis and death in some patients, such as critically ill
patients and other patients suffering from intestinal inflammation
from the improvement of the intestinal integrity.
5. Limitations
The current systematic review summarizes the results from
various animal interventions to determine the possible beneficial
effects of the PC supplementation on human nutrition to improve
the intestinal inflammation, however, the animal results must be
validated in a randomized control trial on humans to determine the
effects of PCs on human intestinal health. A major limitation of the
present review is that because of the complexity and extent of the
information on the effects from the intestinal PC metabolization by
the intestinal microbiota, and their possible effects over the intes-
tinal health have only been briefly mentioned as a part of our work.
However, the authors consider this as a major topic of increasing
interest amongst the scientific community and it is worthy of study12in future reviews focusing both on the microbiota and intestinal
barrier.
6. Conclusions
From the present systematic review, in animals, the oral
administration of various PCs improves the intestinal barrier
integrity and function from three main mechanisms: 1) The
reduction of several pro-inflammatory molecules, 2) the improve-
ment in the expression of TJ proteins, and 3) the improvement of
the antioxidant intracellular activity from chemical interactions
and the increased expression of antioxidant enzymes. Furthermore,
resveratrol, the most studied PC in different animal models of in-
testinal damage, improves the intestinal barrier integrity through
an increase in the expression of various anti-inflammatory and
antioxidant proteins in animals. Thus, suggesting the possible use
of resveratrol or other PCs in the management of the intestinal
injury associated with various intestinal and systemic pathologies
in humans. However, the precise dose and time for the oral
administration of resveratrol or other PCs in humans are still
undetermined.
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[37] Anhê FF,RoyD,PilonG,Dudonne S,MatamorosS,VarinTV,etal.Apolyphenol-rich
cranberry extract protects from diet-induced obesity, insulin resistance and in-
testinal inflammation in association with increased Akkermansia spp. population
in the gutmicrobiota ofmice. Gut 2015 Jun 1;64(6):872e83 [Internet] [cited 2020
Aug 9] Available from: https://pubmed.ncbi.nlm.nih.gov/25080446/.
[38] Yang G, Wang H, Kang Y, Zhu MJ. Grape seed extract improves epithelial
structure and suppresses inflammation in ileum of IL-10-deficient mice. Food
Funct 2014 Oct 1;5(10):2558e63.
[39] Yang G, Xue Y, Zhang H, Du M, Zhu MJ. Favourable effects of grape seed
extract on intestinal epithelial differentiation and barrier function in IL10-
deficient mice. Br J Nutr 2015 Jul 14;114(1):15e23.
[40] Boussenna A, Joubert-Zakeyh J, Fraisse D, Pereira B, Vasson MP, Texier O, et al.
Dietary supplementation with a low dose of polyphenol-rich grape pomace
extract prevents dextran sulfate sodium-induced colitis in rats. J Med Food
2016 Aug 1;19(8):755e8 [Internet] [cited 2020 Aug 11] Available from:
https://pubmed.ncbi.nlm.nih.gov/27355494/.
[41] Wang N, Han Q, Wang G, Ma WP, Wang J, Wu WX, et al. Resveratrol protects
oxidative stress-induced intestinal epithelial barrier dysfunction by upre-
gulating heme oxygenase-1 expression. Dig Dis Sci 2016 Sep 1;61(9):
2522e34.
[42] Vezza T, Algieri F, Rodríguez-Nogales A, Garrido-Mesa J, Utrilla MP,
Talhaoui N, et al. Immunomodulatory properties of Olea europaea leaf extract
in intestinal inflammation. Mol Nutr Food Res 2017 Oct 1;61(10):1601066.
https://doi.org/10.1002/mnfr.201601066 [Internet] [cited 2020 Aug 11]
Available from:.
[43] Mayangsari Y, Suzuki T. Resveratrol ameliorates intestinal barrier defects and
inflammation in colitic mice and intestinal cells. J Agric Food Chem 2018 Dec
5;66(48):12666e74 [Internet] [cited 2020 Aug 9] Available from: https://
pubmed.ncbi.nlm.nih.gov/30426751/.
[44] Chen J, Yu B, Chen D, Huang Z, Mao X, Zheng P, et al. Chlorogenic acid im-
proves intestinal barrier functions by suppressing mucosa inflammation and
improving antioxidant capacity in weaned pigs. J Nutr Biochem 2018 Sep
1;59:84e92.
B.A. Sandoval-Ramírez, Ú. Catalan, A. Pedret et al. Clinical Nutrition xxx (xxxx) xxx[45] Cao S, Shen Z, Wang C, Zhang Q, Hong Q, He Y, et al. Resveratrol improves
intestinal barrier function, alleviates mitochondrial dysfunction and induces
mitophagy in diquat challenged piglets 1. Food Funct 2019 Jan 1;10(1):
344e54 [Internet] [cited 2020 Aug 9] Available from: https://pubmed.ncbi.
nlm.nih.gov/30601541/.
[46] Guo K, Ren J, Gu G, Wang G, Gong W, Wu X, et al. Hesperidin protects against
intestinal inflammation by restoring intestinal barrier function and up-
regulating Treg cells. Mol Nutr Food Res 2019 Jun 1;63(11) [Internet] [cited
2020 Aug 11] Available from: https://pubmed.ncbi.nlm.nih.gov/30817082/.
[47] Sun X, Du M, Navarre DA, Zhu MJ. Purple potato extract promotes intestinal
epithelial differentiation and barrier function by activating AMP-activated
protein kinase. Mol Nutr Food Res 2018 Feb 1;62(4).
[48] Carmona-Hernandez JC, Taborda-Ocampo G, Valdez JC, Bolling BW, Gonzalez-
Correa CH. Polyphenol extracts from three Colombian passifloras (passion
fruits) prevent inflammation-induced barrier dysfunction of Caco-2 cells.
Molecules 2019 Dec 17;24(24).
[49] Carrasco-Pozo C, Morales P, Gotteland M. Polyphenols protect the epithelial
barrier function of Caco-2 cells exposed to indomethacin through the mod-
ulation of occludin and zonula occludens-1 expression. J Agric Food Chem
2013 Jun 5;61(22):5291e7.
[50] Wan MLY, Ling KH, Wang MF, El-Nezami H. Green tea polyphenol epi-
gallocatechin-3-gallate improves epithelial barrier function by inducing the
production of antimicrobial peptide pBD-1 and pBD-2 in monolayers of
porcine intestinal epithelial IPEC-J2 cells. Mol Nutr Food Res 2016 May
1;60(5):1048e58.
[51] Ling KH, Wan MLY, El-Nezami H, Wang M. Protective capacity of resveratrol, a
natural polyphenolic compound, against deoxynivalenol-induced intestinal
barrier dysfunction and bacterial translocation. Chem Res Toxicol 2016 May
16;29(5):823e33.
[52] Wong X, Carrasco-Pozo C, Escobar E, Navarrete P, Blachier F, Andriamihaja M,
et al. Deleterious effect of p-cresol on human colonic epithelial cells prevented
by proanthocyanidin-containing polyphenol extracts from fruits and proan-
thocyanidin bacterial metabolites. J Agric Food Chem 2016 May 11;64(18):
3574e83.
[53] Mayangsari Y, Suzuki T. Resveratrol ameliorates intestinal barrier defects and
inflammation in colitic mice and intestinal cells. J Agric Food Chem 2018 Dec
5;66(48):12666e74.
[54] Singh R, Chandrashekharappa S, Bodduluri SR, Baby BV, Hegde B, Kotla NG,
et al. Enhancement of the gut barrier integrity by a microbial metabolite
through the Nrf2 pathway. Nat Commun 2019 Dec 1;10(1).14[55] Gan Z, Wei W, Li Y, Wu J, Zhao Y, Zhang L, et al. Curcumin and resveratrol
regulate intestinal bacteria and alleviate intestinal inflammation in weaned
piglets. Molecules 2019 Mar 28;24(7) [Internet] [cited 2020 Aug 9] Available
from: https://pubmed.ncbi.nlm.nih.gov/30925757/.
[56] Keubler LM, Buettner M, H€ager C, Bleich A. A multihit model: colitis lessons
from the interleukin-10-deficient mouse. Inflamm Bowel Dis 2015 Apr
29;21(8):1967e75.
[57] Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Moullan N, Nicolet-Dit-
Felix AA, et al. Urolithin A induces mitophagy and prolongs lifespan in C.
elegans and increases muscle function in rodents. Nat Med 2016 Aug 1;22(8):
879e88.
[58] Singer P, Blaser AR, Berger MM, Alhazzani W, Calder PC, Casaer MP, et al.
ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr
2019;38(1):48e79. https://doi.org/10.1016/j.clnu.2018.08.037 [Internet]
[cited 2020 Feb 4] Available from:.
[59] Tian F, Heighes PT, Allingstrup MJ, Doig GS. Early enteral nutrition provided
within 24 hours of ICU admission: a meta-analysis of randomized controlled
trials. Crit Care Med 2018;46(7):1049e56.
[60] Pu H, Doig GS, Heighes PT, Allingstrup MJ. Early enteral nutrition reduces
mortality and improves other key outcomes in patients with major burn
injury: a meta-analysis of randomized controlled trials. Crit Care Med
2018;46(12):2036e42.
[61] Rupani B, Caputo FJ, Watkins AC, Vega D, Magnotti LJ, Lu Q, et al. Relationship
between disruption of the unstirred mucus layer and intestinal restitution in
loss of gut barrier function after trauma hemorrhagic shock. Surgery 2007
Apr;141(4):481e9 [Internet] [cited 2020 Mar 3] Available from: http://www.
ncbi.nlm.nih.gov/pubmed/17383525.
[62] Otani S, Coopersmith CM. Gut integrity in critical illness. J Intensive Care 2019
Mar 20;7(1):17 [Internet] [cited 2020 Mar 3] Available from: https://
jintensivecare.biomedcentral.com/articles/10.1186/s40560-019-0372-6.
[63] Possemiers S, Bolca S, Verstraete W, Heyerick A. The intestinal microbiome: a
separate organ inside the body with the metabolic potential to influence the
bioactivity of botanicals. Fitoterapia Fitoterapia 2011;82:53e66 [Internet]
[cited 2020 Aug 28] Available from: https://pubmed.ncbi.nlm.nih.gov/
20655994/.
[64] Garcia-Mu~noz C, Vaillant F. Metabolic fate of ellagitannins: implications for
health, and research perspectives for innovative functional foods. Crit Rev
Food Sci Nutr 2014;54(12):1584e98 [Internet] [cited 2020 Aug 26] Available
from: https://pubmed.ncbi.nlm.nih.gov/24580560/.
